Free Trial

Neuphoria Therapeutics Inc. - Common Stock Q2 2025 Earnings Report

Neuphoria Therapeutics Inc. - Common Stock logo
$4.88 -0.17 (-3.37%)
As of 02/21/2025 04:00 PM Eastern

Neuphoria Therapeutics Inc. - Common Stock EPS Results

Actual EPS
-$1.23
Consensus EPS
-$2.01
Beat/Miss
Beat by +$0.78
One Year Ago EPS
N/A

Neuphoria Therapeutics Inc. - Common Stock Revenue Results

Actual Revenue
$660.00 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Neuphoria Therapeutics Inc. - Common Stock Announcement Details

Quarter
Q2 2025
Time
Before Market Opens

Conference Call Resources

Neuphoria Therapeutics Inc. - Common Stock Earnings Headlines

See More Neuphoria Therapeutics Inc. - Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics Inc. - Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics Inc. - Common Stock and other key companies, straight to your email.

About Neuphoria Therapeutics Inc. - Common Stock

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

View Neuphoria Therapeutics Inc. - Common Stock Profile

More Earnings Resources from MarketBeat